Search
Displaying 171–180 of 735 for “retinitis clinical trial”
-
FFB-Funded Scientists Report on Nine Promising Translational Research Efforts
Research NewsThe Foundation Fighting Blindness has taken the translational challenge head on by investing more than $75 million in therapy-development projects with strong clinical-trial potential through its Translational Research Acceleration Program (TRAP), which includes Gund-Harrington Scholar Awards.
-
Foundation Fighting Blindness Provides Public Access to Data From its RUSH2A Natural History Study
Foundation NewsRUSH2A has captured extensive data over four years from patients with USH2A mutations causing non-syndromic retinitis pigmentosa and Usher syndrome type 2A.
-
Research News
Microperimetry, which measures retinal sensitivity in the macular region, shows promise as outcome measure
-
Forty-Four High-Impact Retinal-Research Efforts Highlighted at FFB-Casey Innovation Summit
Research NewsIn its fourth year, the meeting is becoming the world’s most comprehensive overview of the promising research underway for emerging IRD treatments.
-
Forty High-Impact Retinal-Research Efforts Highlighted at FFB-Casey Innovation Summit
Research NewsIn its fifth year, the Innovation Summit featured 40 presentations from industry experts from around the world.
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2020 (July 1, 2019-June 30, 2020)
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2021 (July 1, 2020–June 30, 2021)
-
Seeing Research Advances Firsthand
Beacon StoriesMark does not let his retinitis pigmentosa diagnosis keep him from doing what he loves most, including spending quality time with his family. And in 2019, Mark began participating in a clinical trial, which he describes as life-changing.
-
Foundation Funds 25 New Grants Totaling $15.1 Million in FY23
Research NewsThe global leader in retinal degenerative disease research supports a total of 93 research grants in its portfolio.
-
Research News
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States
First adeno-associated viral (AAV) vector investigational candidate to reach this stage of FDA review
Investigational LUXTURNA clinical program includes up to four years of efficacy data, with observation ongoing
